Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Current Assets (2016 - 2025)

Vanda Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $347.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 20.88% year-over-year to $347.3 million; the TTM value through Dec 2025 reached $347.3 million, down 20.88%, while the annual FY2025 figure was $347.3 million, 20.88% down from the prior year.
  • Current Assets for Q4 2025 was $347.3 million at Vanda Pharmaceuticals, down from $367.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $536.6 million in Q3 2023 and bottomed at $347.3 million in Q4 2025.
  • The 5-year median for Current Assets is $443.0 million (2021), against an average of $456.4 million.
  • The largest annual shift saw Current Assets increased 18.55% in 2021 before it decreased 20.88% in 2025.
  • A 5-year view of Current Assets shows it stood at $478.3 million in 2021, then rose by 8.57% to $519.3 million in 2022, then fell by 16.63% to $432.9 million in 2023, then increased by 1.37% to $438.9 million in 2024, then fell by 20.88% to $347.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Current Assets are $347.3 million (Q4 2025), $367.5 million (Q3 2025), and $394.9 million (Q2 2025).